Stocks · News reference
Akari Therapeutics reports positive preclinical data for AKTX-101 in urothelial cancer, showing efficacy in models resistant to current ADCs.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced new preclinical data demonstrating the
Read original at benzingaExpanded the Company's strategic position in novel ADC payloads through a research collaboration on dual ADC payloads with Whitehawk Therapeutics to evaluate Akari's proprietary PH1 spliceosome modulating
Read original at benzingaAkari Therapeutics announced a strategic research collaboration with WhiteHawk Therapeutics to combine Akari's PH1 spliceosome-modulating payload with WhiteHawk's TOP1 inhibitor ADC platform for a novel dual-payload strategy. The company is advancing its lead candidate AKTX-101 toward Phase 1 clinical evaluation by mid-2027 and emphasizes that collaborations will play an increasingly important role in advancing next-generation ADC innovation.
Read original at globenewswire-inc